Diabetes is a complex, difficult condition to manage and mitigating the progression of the disease is essential to prevent secondary complications. Intellin® is an intelligent diabetes management platform that uses clinical data to predict the trajectory of the individual’s disease and helps to mitigate progression through smart tips.
The potential of Intellin® was recognised early by Health Innovation Manchester (HInM) and the Innovation Agency, the AHSN for the North West Coast, who have supported the developers, Gendius Limited, with bespoke and relevant business support, funding for two important projects and important introductions throughout all stages of the innovation.
A National Institute for Health Research (NIHR) portfolio study in Diabetic Foot Ulcer launched it’s findings in December 2020, and a trial and Real World Validation is about to start in NHS Oldham CCG using the Intellin® app and the connected Healthcare Professional Dashboard.
To date, Intellin® has been downloaded over 300,000 times in 170 countries. A strong academic partnership with the University of Nottingham has grown over several years, and 2020 saw a partnership agreement signed with Astra Zeneca. Intellin® will also be launched into the Gulf States in early Autumn.
Interest in Remote monitoring solutions for diabetes management offer the potential for reduction in journeys to access care, as well as more efficient use of time in surgery or clinic.
As an AHSN, HInM have been supporting Gendius since mid-2016. Highlights include:
- Putting together a consortium that included Salford Royal NHS Foundation Trust to apply for an Innovate UK grant. HInM were pivotal in helping Gendius to structure the study, which won over £500,000 to carry out the INDUCE study.
- Bespoke business support under ERDF Programme including User Experience Design U/X support and advice.
- Brokering conversations with clinicians and other NHS stakeholders.
- Two funding awards under HInM Momentum competitive process.
- Brokering introductions to demo Intellin® and pitch for VC funding at a European/global scale at the HIMSS-Health 2.0 European Conference in Helsinki in June 2019.
- Real World Validation support in Partnership with University of Chester and NHS Oldham CCG.
- Gendius has been successful in attracting investment from a number of sources including government funding (Innovate UK, SBRI), Venture Capitalists, High Net Worth Individuals and Crowdfunding. Total investment is now close to £2 million.
- Secured two funding awards through the HInM Momentum Funding call
- £12,000 awarded in 2017 to support market research activity and carry out in depth research into the requirements of customers for the development of the platform.
- £50,000 awarded in March 2020 to further develop the Intellin® platform and analyse consented patient data across 250 GPs/1,000+ patients to help improve the existing algorithms that are used to predict a patient’s risk of developing complications from their diabetes.
- Company expansion, international deals and support from the AHSN Network have led to the following 11 jobs being created: lead developer, U/X designer, part time chief scientific officer, lead QA, NHS Partnership director, social media manager, full stack developer, data scientist, operations manager, quality assurance tester, and a marketing and social media executive. It is anticipated that further jobs will be created in the next six months.
- Memorandum of Understanding signed with Astra Zeneca to develop Intellin® and support patients in Gulf Cooperation Council (GCC) countries, which have some of the highest rates of diabetes in the world.
Patient and other Impacts:
- A study in Salford, looking at the prevention of recurrence of diabetic foot ulcer, closed in April 2020 and is due to report in Autumn 2021. Ethically, it is not possible to comment on results but is hoped that it will be presented at conferences in 2021.
- 300,000 downloads, more than 60,000 monthly users, in 170 countries.
- The advent of the coronavirus (COVID-19) era has seen diabetes support services such as podiatry, retinopathy and HbA1c test suspended for the foreseeable future. Use of remote consultations is expected to increase post-coronavirus and Intellin®, with its predictive capacity is poised to make a significant contribution to this space.
HInM Support will continue under the Health Matters ERDF project under 2023 to document a Real World Validation in partnership with the University of Chester and Oldham CCG.
The strategic global partnership that Gendius has with Astra Zeneca offers huge national and international opportunity. Additionally, discussions are well advanced with a global insurance company regarding implementation of intellin® in Hong Kong.
The data that is gathered by this significant and rapid scaling of the business will allow for ever-increasing accuracy of the clinical algorithms. This is turn will increasing the potential positive impact on reduction of disease progression.
Gaining traction within the NHS remains a major challenge for innovative tech companies. Gendius would like the opportunity to trial the app more widely to refine the cost-benefit analysis for the NHS.
- Company and AHSN support commenced in 2016. Enrolment in ERDF Business support in March 2017 – support still ongoing under Health Innovation Manchester ERDF project Health Matters in partnership with Innovation Agency.
- Real World Validation support expected to be reviewed Q1 2021 (Under ERDF – University of Chester) – Momentum Grant review in March 2021.
Project contact for further information:
Daniel Zamora, Commercial Programme Manager, Health Innovation Manchester
M:077 021 52557
Lucy Williams, Senior Communications Officer, Health Innovation Manchester
Company contact for further information:
Chris Genders, Co-founder & CPO, Gendius Limited